UniQure’s Huntington’s Disease Therapy Faces FDA Delay | STAT+ Exclusive

The path to potential FDA approval for UniQure’s gene therapy for Huntington’s disease has hit another roadblock. The company announced Monday that regulators continue to express reservations about the data supporting its application, requiring a more rigorous, controlled trial before considering approval. This setback impacts not only UniQure, but also the broader field of gene therapy development for neurodegenerative diseases, and offers a stark reminder of the high bar for demonstrating efficacy and safety in these complex conditions.

FDA Calls for Randomized, Controlled Trial

Following a meeting with the Food and Drug Administration at the complete of January, UniQure learned that the existing data from a single-arm clinical trial of its gene therapy, known as AMT-130, are insufficient to warrant a marketing application. A single-arm trial, where all participants receive the treatment without a comparison group, can demonstrate a signal of efficacy, but is generally considered less definitive than studies with a control group. The FDA has “strongly recommended” that UniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study, according to the company’s statement. Stat News reported on the development Monday.

This type of trial is considered the gold standard in clinical research. “Randomized” means participants are assigned to either the treatment group or a control group (in this case, a sham surgery) by chance. “Double-blind” means neither the participants nor the researchers know who is receiving the actual treatment versus the sham procedure, minimizing bias. A “sham surgery” involves mimicking the surgical procedure without actually administering the gene therapy, allowing researchers to isolate the effects of the treatment itself.

Huntington’s Disease and the Promise of Gene Therapy

Huntington’s disease is a progressive, inherited neurological disorder that causes the breakdown of nerve cells in the brain. Symptoms typically develop in adulthood and include movement, cognitive, and psychiatric disturbances. Currently, treatments focus on managing symptoms, but there is no cure. The disease is caused by a mutation in the HTT gene, which produces a toxic protein that damages brain cells.

Gene therapy, like UniQure’s AMT-130, aims to address the root cause of the disease by delivering a functional copy of the HTT gene or silencing the mutated gene. AMT-130 uses an adeno-associated virus (AAV) vector to deliver a gene-silencing RNA molecule directly into the brain, aiming to reduce the production of the harmful Huntington protein. Previous reporting from Stat News detailed the initial promising results from the single-arm trial, which showed a slowing of disease progression in some patients.

Understanding the FDA’s Concerns: Trial Design and Data Interpretation

The FDA’s request for a randomized, controlled trial underscores the challenges inherent in evaluating gene therapies, particularly for slowly progressing diseases like Huntington’s. In a single-arm trial, it can be challenging to determine whether observed improvements are due to the treatment itself or to natural fluctuations in the disease course, or even the placebo effect.

The agency’s concern likely stems from the inherent variability in Huntington’s disease progression. Without a control group, it’s challenging to definitively attribute any observed changes solely to the gene therapy. The FDA needs robust evidence to ensure that the benefits of the treatment outweigh the potential risks, especially considering the invasive nature of the procedure – direct injection of the gene therapy into the brain.

Implications for UniQure and the Gene Therapy Field

This decision represents a significant setback for UniQure, which has invested heavily in the development of AMT-130. Conducting a large-scale, randomized, controlled trial will be expensive and time-consuming, potentially delaying the availability of the therapy for years. The company’s stock price reportedly fell following the announcement, reflecting investor concerns. Stat News also reported on a recent investor dinner with UniQure’s CEO, where the challenges facing the Huntington’s therapy were discussed.

More broadly, the FDA’s stance highlights the increasing scrutiny of gene therapy applications. While gene therapies hold immense promise for treating previously incurable diseases, regulators are demanding rigorous evidence of efficacy and safety before approving these novel treatments. This cautious approach is essential to protect patients and ensure the long-term viability of the gene therapy field.

What Comes Next: A Long Road Ahead

UniQure has stated its intention to work with the FDA to design and implement the required clinical trial. The company will need to secure funding, recruit patients, and navigate the logistical complexities of conducting a multi-center, randomized, controlled study. The timeline for completing the trial and submitting a modern marketing application remains uncertain, but We see likely to take several years.

For patients with Huntington’s disease and their families, this news is undoubtedly disappointing. However, it’s important to remember that research into Huntington’s disease is ongoing, and several other gene therapy approaches are in development. Continued investment in research and a commitment to rigorous clinical trials are essential to ultimately finding effective treatments for this devastating disease. Individuals affected by Huntington’s disease should continue to consult with their healthcare providers for the latest information and guidance.